Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The transpeptidase domain within Penicillin-Binding Proteins (PBPs) is responsible for catalyzing the cross-linking of peptidoglycan chains, providing structural integrity to the bacterial cell wall. The active site, characterized by conserved motifs (SxxK, SxN, KTGT) and key residues (e.g., Ser294, Lys333, Asp447), is the primary target for β-lactam antibiotics. These antibiotics inhibit activity by covalently binding to the active-site serine, mimicking the natural substrate (D-Ala-D-Ala) and forming a stable acyl-enzyme complex, thus blocking cell wall synthesis and leading to bacterial death. Resistance can arise through mutations or low-affinity PBP variants.
Irreversible inhibition of transpeptidase activity via covalent binding to the active site serine residue, preventing peptidoglycan cross-linking.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Penicillin-Binding Protein Transpeptidase Active Site (PBP Transpeptidase Active Site).